Novartis (NOVN) PT Set at CHF 79 by HSBC

HSBC set a CHF 79 price target on Novartis (VTX:NOVN) in a research report report published on Thursday, July 19th. The firm currently has a neutral rating on the stock.

A number of other analysts have also issued reports on the stock. Jefferies Financial Group set a CHF 98 price target on shares of Novartis and gave the stock a buy rating in a research report on Friday, April 13th. Cfra set a CHF 91 price target on shares of Novartis and gave the stock a buy rating in a research report on Tuesday, March 27th. Baader Bank set a CHF 95 price target on shares of Novartis and gave the stock a buy rating in a research report on Tuesday, March 27th. Oddo Bhf set a CHF 88 price target on shares of Novartis and gave the stock a buy rating in a research report on Wednesday, March 28th. Finally, Sanford C. Bernstein set a CHF 97 price target on shares of Novartis and gave the stock a buy rating in a research report on Monday, April 9th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the company. Novartis currently has an average rating of Hold and an average target price of CHF 88.65.

Shares of Novartis traded up CHF 0.34, hitting CHF 78.38, during midday trading on Thursday, according to MarketBeat Ratings. The stock had a trading volume of 11,210,000 shares, compared to its average volume of 5,980,000. Novartis has a fifty-two week low of CHF 72.45 and a fifty-two week high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Article: How to Invest in Growth Stocks

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply